About the Barrie Dalgleish Centre

With initial funding through a bequest of $15M from the Estate of Barrie Dalgleish, The Barrie Dalgleish Centre for Myeloma and Related Blood Cancers is a partnership of academic organisations, lead out of Peter Mac, that drives new fundamental, clinical and health services multiple myeloma research in an integrated, interdisciplinary, and collaborative manner.

BarrieDalgleish Centre Lockup RGB Horiz FC

Multiple myeloma (MM), a malignancy of plasma cells that develops within the bone marrow, represents the second most frequently diagnosed form of blood cancer. Despite major therapeutic progress in the last two decades, MM is generally considered incurable with currently available standard of care treatments.

This year around 2,600 Australians will be diagnosed with myeloma and this cancer, which affects white blood cells, will claim 1,100 lives. The chance of survival after five years is currently 55%.

Blood cancer as a group (including lymphomas and leukaemias) ranks alongside prostate and breast cancer in terms of new diagnoses each year in Australia and is a leading cause of cancer deaths, equivalent to deaths from lung and colorectal cancer. Each year 19,400 Australians find out they have blood cancer and each year 5,950 lose their lives to blood cancer or related blood disorders.

Researchers from the Peter Mac, as well as others in and around the Parkville precinct, have established programs of multiple myeloma research that aim to:

  • understand the genetic and biological events that underpin multiple myeloma onset and progression
  • develop physiologically relevant pre-clinical models to study the disease and develop novel therapies
  • utilise clinical samples and data to improve outcomes for patients

The Barrie Dalgleish Centre for Myeloma and Related Blood Cancers harnesses the collective human talent, resources and equipment from across Peter Mac and our partner organisations to enhance our knowledge of the biological and molecular causes of multiple myeloma, develop new diagnostic and therapeutic options, and ultimately put in place new treatment modalities for patients. Partners include WEHI, University of Melbourne, Royal Melbourne Hospital, St Vincent’s Medical Research Institute and St Vincent’s Hospital.

The Centre’s mission is to make new discoveries in multiple myeloma research that will lead to translatable outcomes important not just for multiple myeloma, but for other types of blood cancers.

Hear from a Peter Mac myeloma patient